376638-65-2 Usage
Uses
Used in Pharmaceutical Industry:
BVT-14225 is used as a therapeutic agent for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is utilized for its ability to relax smooth muscle cells in the airways, thereby improving lung function. BVT-14225's mechanism of action is based on the inhibition of cyclic adenosine monophosphate (cAMP) breakdown, leading to muscle relaxation and enhanced respiratory function.
Additionally, BVT-14225 is used as an anti-inflammatory agent in the treatment of respiratory conditions. Its anti-inflammatory properties suggest potential use in reducing airway inflammation, which is a common feature in various respiratory diseases. BVT-14225's dual action of muscle relaxation and inflammation reduction positions it as a promising candidate for further research and clinical trials to assess its efficacy and safety in medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 376638-65-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,7,6,6,3 and 8 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 376638-65:
(8*3)+(7*7)+(6*6)+(5*6)+(4*3)+(3*8)+(2*6)+(1*5)=192
192 % 10 = 2
So 376638-65-2 is a valid CAS Registry Number.
376638-65-2Relevant academic research and scientific papers
Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1
Barf, Tjeerd,Vallg?rda, Jerk,Emond, Rikard,H?ggstr?m, Charlotta,Kurz, Guido,Nygren, Alf,Larwood, Vivienne,Mosialou, Erifili,Axelsson, Kent,Olsson, Rolf,Engblom, Lars,Edling, Naimie,R?nquist-Nii, Yuko,?hman, Birgitta,Alberts, Peteris,Abrahmsén, Lars
, p. 3813 - 3815 (2007/10/03)
Novel antidiabetic arylsulfonamidothiazoles are presented that exert action through selective inhibition of the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme, thereby attenuating hepatic gluconeogenesis. The diethylamide derivative 2a was shown to potently inhibit human 11β-HSD1 (IC50 = 52 nM), whereas the N-methylpiperazinamide analogue 2b only inhibited murine 11β-HSD1 (IC50 = 96 nM). Both compounds showed >200-fold selectivity over human and murine 11β-HSD2. 2b was subsequently shown to reduce glucose levels in diabetic KKAy mice, substantiating the 11β-HSD1 enzyme as a target for the treatment of type 2 diabetes.
